Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-05212384 + irinotecan
- Development stage
- Discontinued
- Lead developer
- Pfizer
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
PF-05212384 (gedatolisib, also known as PKI-587) is an investigational, intravenous, dual inhibitor of phosphoinositide 3‑kinase (PI3K) and mammalian target of rapamycin (mTOR), developed for the treatment of advanced solid tumors. When combined with irinotecan—a topoisomerase I inhibitor chemotherapy—the regimen aims to enhance antitumor activity by targeting both cell signaling pathways involved in tumor growth and DNA replication. This combination has been studied primarily in patients with advanced or metastatic colorectal cancer, particularly those with KRAS and NRAS wild-type tumors. Clinical trials have shown a modest response rate (~5%) and some clinical benefit in this population[1][2][3]. The combination is administered intravenously on a repeating cycle schedule.
- Other names
- PKI-587 + irinotecangedatolisib + irinotecan
02
Targets
TOP1 (DNA Topoisomerase I)mTOR (Mammalian target of rapamycin kinase)PIK3CA (Phosphoinositide 3-kinase alpha)
Beyond the preview
Go deeper on PF-05212384 + irinotecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-05212384 + irinotecan.